title: Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients.
authors.affiliation: Department of Therapeutic Immunology, Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, SE-141 86, Stockholm, Sweden. mats.remberger@ki.se
authors.forename: Mats
authors.initials: M
authors.lastname: Remberger
authors.forename: Olle
authors.initials: O
authors.lastname: Ringdén
mesh_terms: D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000077561:Daclizumab; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology / Q000601:surgery* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007239:Infections / Q000209:etiology; D000069285:Infliximab; D053208:Kaplan-Meier Estimate; D045164:Mesenchymal Stem Cell Transplantation; D011701:PUVA Therapy; D017893:Photopheresis; D012189:Retrospective Studies; D000069283:Rituximab; D020123:Sirolimus / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069283:Rituximab; D000069285:Infliximab; D000077561:Daclizumab; D020123:Sirolimus